Sabato 27 ottobre 2012 - Pacini Editore
Sabato 27 ottobre 2012 - Pacini Editore
Sabato 27 ottobre 2012 - Pacini Editore
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
394<br />
Immunoreactions were revealed us-<br />
Fig. 1.<br />
ing a streptavidin-biotin enhanced<br />
immunoperoxidase technique (Super<br />
Sensitive MultiLink, Menarini, Florence,<br />
Italy) in an automated autostainer.<br />
Receiver Operative Curve<br />
(ROC) analysis was adopted for<br />
optimal cut-off values. Evaluation<br />
of the immunohistochemical results,<br />
blinded to all patient data, was performed<br />
independently and in blinded<br />
manner by two investigators (MM<br />
and FN). Statistical analyses: Multiple<br />
Correspondence Analysis (MCA)<br />
was used to identify sub-groups of<br />
BC patients with different prognosis,<br />
while uni-and multivariate Cox<br />
regression analyses were applied to<br />
determine the impact of parameters<br />
identified by MCA on 10-yrs Disease<br />
Free Survival (DFS), together<br />
with clinico-pathological features.<br />
Results. In our series of 133 BC<br />
patients (median follow-up of 107<br />
months) the MCA analysis (Fig. 1)<br />
demonstrates the contrast between<br />
high Ki67/p53+/p-Akt+/PI3K+/<br />
HER2+ (Adverse Biologic Factors,<br />
ABF) and presence of relapse (upper<br />
right quadrant) vs low Ki67/<br />
p53–/p-Akt–/PI3K–/HER2– BC and<br />
no relapse (lower left quadrant).<br />
Therefore, this statistical approach Fig. 2.<br />
may define an Unfavorable Biologic<br />
Profile (UBP) associated to disease<br />
progression considering the presence/absence<br />
of at least 3 variables<br />
out of the 5 selected as discriminative<br />
power, (UBP≥3 ABF) and a<br />
Favourable Biologic Profile (FBP